Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

The Florida-based provider will work with AI software company AiraMed to analyze and measure patients' brain volume from MRIs.

A critical review of the limitations posed by current preclinical animal models of Alzheimer's disease and of the oversimplistic assumptions proposed by the amyloid cascade hypothesis (ACH).

Annovis Bio saw promising results for Buntanetap in treating Alzheimer's and Parkinson's, but short cash runway prompts a ...

A report published Wednesday in The BMJ questioned the safety and effectiveness of the Alzheimer’s disease drug Kisunla ...

An investigation, published in the journal The BMJ, found that the newly U.S. Food & Drug Administration-approved donanemab is linked ...

In the US, the FDA approved a new Alzheimer's treatment in July 2024 called donanemab. The treatment is for people with early symptomatic Alzheimer's disease, including mild cognitive impairment and ...

A startling investigation has revealed a troubling story behind donanemab's approval -- one of questionable data, potential ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

Japan’s Ministry of Health, Labour and Welfare granted new drug approvals and expanded indications for conditions like cancer, insomnia and Alzheimer’s disease (AD) Sept. 24, including Eli Lilly and ...

A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...

The safety and effectiveness of donanemab—an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA)—is ...